Myocardial Inflammation as a Manifestation of Genetic Cardiomyopathies: From Bedside to the Bench

Biomolecules. 2023 Apr 4;13(4):646. doi: 10.3390/biom13040646.

Abstract

Over recent years, preclinical and clinical evidence has implicated myocardial inflammation (M-Infl) in the pathophysiology and phenotypes of traditionally genetic cardiomyopathies. M-Infl resembling myocarditis on imaging and histology occurs frequently as a clinical manifestation of classically genetic cardiac diseases, including dilated and arrhythmogenic cardiomyopathy. The emerging role of M-Infl in disease pathophysiology is leading to the identification of druggable targets for molecular treatment of the inflammatory process and a new paradigm in the field of cardiomyopathies. Cardiomyopathies constitute a leading cause of heart failure and arrhythmic sudden death in the young population. The aim of this review is to present, from bedside to bench, the current state of the art about the genetic basis of M-Infl in nonischemic cardiomyopathies of the dilated and arrhythmogenic spectrum in order to prompt future research towards the identification of novel mechanisms and treatment targets, with the ultimate goal of lowering disease morbidity and mortality.

Keywords: arrhythmogenic; bench; cardiac magnetic resonance; cardiomyopathies; desmosomes; dilated; endomyocardial biopsy; genetics; myocardial inflammation; preclinical models; sudden cardiac death; ventricular arrhythmias.

Publication types

  • Review

MeSH terms

  • Arrhythmias, Cardiac / genetics
  • Cardiomyopathies* / genetics
  • Cardiomyopathies* / pathology
  • Heart Failure* / complications
  • Humans
  • Inflammation / complications
  • Inflammation / genetics
  • Myocarditis* / genetics

Grants and funding

This research received no external funding.